Fibromyalgia

New data links chronic pain to impaired muscle relaxation, with the greatest limitations observed in fibromyalgia and chronic tension-type headache.

Evidence shows fibromyalgia patients face higher overactive bladder rates and symptom severity, highlighting the importance of integrated care.

A compilation of 13 trials presented as late-breaking data at ACR Convergence 2025.

TENS combined with physical therapy significantly alleviates fibromyalgia pain and fatigue.

Q3 2025 saw a number of exciting approvals and data on promising therapies in development.

Q3 2025 saw several new first targeted therapies for rare and more individualized indications in a number of fields.

The rheumatology month in review emphasizes new approvals and the latest comparative research.

Mease discussed his hopes for the new approval's impact on the fibromyalgia field.

Study data favored the placebo group, although differences were not clinically meaningful.

The rheumatology month in review emphasizes new approvals and best-in-class efficacy data.

This FDA News Month in Review provides a round-up of regulatory decisions from August 2025.

The therapy, marketed as Tonmya, is a sublingual formulation of cyclobenzaprine HCl.

Findings from the prospective feasibility study support further evaluation of the 6-week home-based stretching program in a randomized controlled trial.

The rheumatology month in review emphasizes new research in psoriatic arthritis treatments and data from EULAR 2025.

GLP-1 receptor agonists show promise in reducing pain, fatigue, and opioid use in fibromyalgia patients, suggesting a new therapeutic avenue.

This study compared a combined pain neuroscience education and resistance training program with a different training program in women with fibromyalgia.

A study reveals a significant link between poor oral health and increased migraines and body pain in women, highlighting implications for fibromyalgia management.

Explore groundbreaking FDA approvals and clinical trial advancements in rheumatology, offering new hope for patients with rare autoimmune diseases and chronic conditions.

The rheumatology month in review emphasizes new research in RA burden, fibromyalgia treatment, and insights from the EULAR 2025 meeting.

We spotlight 7 impactful regulatory decisions scheduled to occur during the second half of 2025.

New research highlights TNX-102 SL's potential to improve sleep and reduce pain in fibromyalgia, marking a significant advancement in treatment options.

With the exception of duloxetine, milnacipran, and pregabalin, most therapies exhibited insignificant results in reducing pain.

New findings suggest Mu-Lympho-Marker could serve as a reliable biomarker for chronic pain in fibromyalgia, enhancing diagnosis and treatment strategies.

The rheumatology month in review emphasizes new research in gout burden, fibromyalgia management, and innovative lupus treatments.